Ted Mikuls, MD, MSPH, Stokes-Shackleford Professor of Rheumatology, vice chair for research, internal medicine, at the University of Nebraska, discusses findings on urate-lowering therapy and the lack of regional data on gout-related lower-extremity amputation.
Ted Mikuls, MD, MSPH, Stokes-Shackleford Professor of Rheumatology, vice chair for research, internal medicine at the University of Nebraska, led a study that compared rates of lower extremity amputations (LEAs) in US veterans with and without gout, using data from the Veterans Health Administration. Here, he explains how urate-lowering therapy may help prevent LEAs and discusses other areas in which he hopes to see additional research.
Transcript
Were you able to determine if there were any differences by region or between urban and rural areas? Why or why not?
I think those are important questions for additional research. We didn't break the study down by region. I wouldn't anticipate that that would have a meaningful effect on the results. In other words, I don't think that's probably going to confound the results, although I think there may be differences by region that exist and that would be interesting to explore. Certainly, the urban-rural disparities that have been described in a lot of other conditions—including conditions like cardiovascular disease—I think would be important to look at in gout, as well.
There have been some studies suggesting that those disparities do exist in gout. Unfortunately, for this particular study, we really weren't in a position to really accurately define to the degree we'd want to, for lack of a better term, the degree of rurality for these rural patients. There's ways to do that, but that was really beyond the scope for this study.
Are there other findings from your study you would like to see further researched?
The suggestion in our findings that urate control may actually lower the risk of lower-extremity amputation, I think that's really intriguing data. We defined optimal urate-lowering therapy based on goals that have been established by professional organizations as thresholds that we should lower uric acids below when we're treating gout.
When we look at those thresholds and whether these patients have evidence of reaching that goal, it does suggest that that has a protective effect against having a lower-extremity amputation, and that's intriguing data. Now, it doesn't prove that we can go out and prevent all of these from happening in these patients, but it's certainly suggestive, and again, just as a call to arms, to really take pause and ask those questions about gout as you're evaluating a patient for lower-extremity amputation.
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
Polypharmacy Common in Rheumatoid Arthritis, Driving Risk of Serious Drug Interactions
August 13th 2025More than 8 in 10 patients with rheumatoid arthritis were taking 5 or more medications at once, a practice linked to older age, multiple comorbidities, and more than 2000 potential drug-to-drug interactions.
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Accessing pediatric dermatology care is challenging due to a shortage of specialists and general dermatologists' reluctance to treat children, but increasing their comfort level with seeing children could help bridge the gap, explained Elizabeth Garcia Creighton, of University of Colorado School of Medicine.
Read More
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More